TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04876014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Mobile-Based Perinatal Mindfulness Intervention
Description: GMBPMI includes 6 EBMI lessons in 6 weeks, and it will require the participants to do mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. The RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided Mobile-Based Perinatal Mindfulness Intervention
Description: GMBPMI includes 6 EBMI lessons in 6 weeks, and it will require the participants to do mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. The RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice.
Study: NCT05222256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Patients in this group will receive levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: Patients in this group will receive Adrenaline
Study: NCT05144035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH
Description: the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
Study: NCT06403527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided venous access during AF ablation
Description: Ultrasound guided venous access during AF ablation
Study: NCT05288270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aramis
Description: ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~* 1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~* 5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
Study: NCT04295720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds.
Study: NCT05458115

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Patient underwent hepatic R0 resection within a week
Study: NCT05497414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Overnight sleep deprivation.
Study: NCT05431881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Binaural beat
Description: Different frequencies are transmitted in both ears, causing beats. The low frequency sound generated by beats induces brainwaves entrainment.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Silent
Description: Apply a wave file which is created in silence.
Study: NCT05631366

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Avoidance Training
Description: Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Avoidance Training
Description: Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.
Study: NCT05560464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study: NCT05341232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lego Robot Programming Active Challenges
Description: Participants will adapt their own Lego robot programs to achieve specific task goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lego Robot Programming Procedural Methods
Description: Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lego Robot Programming Procedural Methods
Description: Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Board Games
Description: Participants will play board games with each other.
Study: NCT06206356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PNS Injectrode F1
Description: The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy. The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm. The device is placed in a minimally invasive procedure via a standard 18g needle. The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously. Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device. Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal. Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
Study: NCT05939674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
Study: NCT06224400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENC1018 for SAD
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENC1018 for MAD
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
Study: NCT05184049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epalrestat,Mecobalamin
Description: Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin
Description: Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
Study: NCT05098431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps and Rectus Femoris MEP Recording
Description: Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
Study: NCT06150976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT-YS
Description: MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.
Study: NCT05524597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing Intervention
Description: Participants will be asked to write about different kinds of experiences.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Writing Intervention
Description: Participants will be asked to write about different kinds of experiences.
Study: NCT05897580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability - Biofeedback (HRV-BF)
Description: The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion (HP)
Description: The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
Study: NCT05232708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 1.34 mg/mL
Description: Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D, 1.0 mg/mL
Description: Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D, 1.0 mg/mL
Description: Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 1.34 mg/mL
Description: Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Study: NCT05460065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single E4 30 mg
Description: Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single E4 100 mg
Description: Administration of a single i.v. infusion of E4 100 mg (n=6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple E4 100 mg
Description: Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)
Study: NCT05435508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
Study: NCT06341478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: various neoadjuvant therapies
Description: Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: various neoadjuvant therapies
Description: Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: various neoadjuvant therapies
Description: Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: various neoadjuvant therapies
Description: Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
Study: NCT03473288

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will undergo supervised exercise 3 times a week for 10-12 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sedentary
Description: Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
Study: NCT05916365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab solution for injection administered subcutaneously
Study: NCT05686200

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Forearm isometric exercise intervention program
Description: Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm isometric exercise intervention program
Description: Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
Study: NCT05182749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bacteriophage
Description: A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered with sodium bicarbonate solution
Study: NCT05995106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart4U
Description: Mobile app.
Study: NCT05393102

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT05048277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Consultation
Description: Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources.
Study: NCT05969834

Intervention type: DRUG
Intervention: uHCG
Description: Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)

Intervention type: DRUG
Intervention: rHCG
Description: Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)

Intervention type: DRUG
Intervention: uHCG and GnRHa
Description: Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
Study: NCT04856800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains \<1 kcal and 0 g protein
Study: NCT05064436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-BMS-986196
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-BMS-986196
Description: Specified dose on specified days
Study: NCT04764422

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% normal saline for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S vaccine
Description: Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S vaccine
Description: Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S vaccine
Description: Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S vaccine
Description: Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S vaccine
Description: Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
Study: NCT06129708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: The aquatic exercises included 5 minutes of warming up in form of walking and running in water, 20 minutes of aerobic and strengthening exercises of pelvis, abdominal and thigh muscles (Double-leg Squat, lunge, knee flexion and extension, hip flexion and

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The exercise protocol consists of 5 minute warm up, 35 min aerobic exercise and 5 minute cool-down. Exercises high-intensity treadmill-based treatment for primary dysmenorrhea for three days a week ,The Borg Rating of Perceived Exertion (RPE) Scale from 6 ('no exertion at all') to 20 ('maximal exertion') was used to regulate the exercise intensity on the treadmill. Participants were encouraged to increase the speed of the treadmill until they perceived their RPE to be between 14 and 16. or at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70-85% of maximum heart rate (MHR) (16.0-18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale).